Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria
Solomon L. Woldu(The University of Texas Southwestern Medical Center), Yair Lotan(Southwestern Medical Center), Wim Van Criekinge(Ghent University Hospital), Steven J. Jacobsen(Mayo Clinic), David Darling, Joep J. de Jong(Erasmus MC Cancer Institute), Kim E.M. van Kessel(Erasmus University Rotterdam), Jeff Slezak(Kaiser Permanente), Daniel A. Barocas(Vanderbilt University Medical Center), Casey K. Ng(NewYork–Presbyterian Hospital), Stephen A. Boorjian(Mayo Clinic), Shahrokh F. Shariat(Universitätszahnklinik Wien), Wei Shen Tan, John D. Kelly(University College Hospital), Andrew M. Hiar, Sarah Brown(University of Leeds), Robert S. Svatek(The University of Texas at San Antonio Health Science Center), Ronald K. Loo(Kaiser Permanente), Tony Lough
Cited by 30
Related Papers
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
|The Lancet|2021|1.3k
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes
|European Urology|2015|688
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
|Cancer Cell|2016|660
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2023|592